US biosimilars savings: $25 billion over 10 years
This article was originally published in Scrip
Executive Summary
The US congressional budget office (CBO) predicts that creating a biosimilars approval pathway would save $25 billion in total healthcare spending over a decade. However, this amount is modest compared with estimates highlighted by the generics industry and could undercut arguments that legislation is urgently needed to reduce soaring healthcare costs.